Outlook Therapeutics (OTLK) propses public offering

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has commenced an underwritten public offering of its common stock and accompanying warrants exercisable for shares of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Outlook Therapeutics intends to use the net proceeds from the offering for working capital and other general corporate purposes.

BTIG, LLC is acting as sole book-running manager for the offering.

The securities described above are being offered by Outlook Therapeutics pursuant to a shelf registration statement on Form S-3 (No. 333-278340) that was declared effective by the Securities and Exchange Commission (SEC) on April 5, 2024. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website located at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering may be obtained, when available, by contacting: BTIG, LLC, 65 East 55th Street, New York, New York 10022, by telephone at (212) 593-7555 or by email at [email protected].

You May Also Be Interested In

• enVVeno Medical (NVNO) files $100M mixed shelf
• Andersen closes secondary offering of 4.9M shares at $44 each
• MicroCloud Hologram acquires 140,268 MicroStrategy shares via structured note